• Non-small cell lung cancer (NSCLC)

Rahika 150mg tablet is a kinase inhibitor that targets mesenchymal-epithelial transition (MET). It works by blocking the action of this abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells.

Inform your healthcare provider about all the medicines you take, including prescription medications, over-the-counter medications, vaccinations, nutritional and vitamin supplements, and herbal products. Certain medications interact with Rahika 150mg tablet and reduce its effectiveness by causing undesirable side effects. 

• Store at 20°C to 25°C
• Protect the medicine from light and excessive moisture.
• Keep the medicine out of reach of children and pets
• If you forgot to take the tablet, take your next dose at the scheduled time. Do not take a double dose to make up for a forgotten dose.

It is an orally available prescription drug. Your doctor will decide the dose and duration of Rahika 150mg tablet based on the disease condition and other factors. Always take this medicine as prescribed by your doctor. Take the tablet with or without food. Do not break, chew, crush, or break the tablet. Swallow the whole tablet with water. 

Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them. 

Common 

• Swelling in the face, and body
• Decrease in appetite
• Nausea
• Cough
• Fatigue 

Serious  

• Vomiting
• Liver injury
• Muscle pain
• Shortness of breath
• Lung infection
• Respiratory disease

Limit direct exposure to the sun or artificial ultraviolet (UV) light while using this medicine. Use sunscreen, wear sunglasses and protective clothing while you are going outdoors, and for at least 7 days after you stop taking it. Report immediately to your doctor if you have abdominal pain. This medicine may cause birth defects if either partner is using it during conception or pregnancy. If you are a female patient with reproductive potential, use an effective form of birth control during the treatment and for 1 week after the last dose. Male patients with female partners should use an effective form of birth control during treatment and for at least 1 week after the last dose. Do not breastfeed while using this medicine and for at least 1 week after your last dose. Your doctor may do lab tests to check the therapy's effectiveness or monitor the unwanted side effects. 

1. Capmatinib Tablets, PIL.; 2022. Accessed May 2, 2023. https://www.ema.europa.eu/en/documents/product-information/tabrecta-epar-product-information_en.pdf
2. TABRECTATM - Capmatinib Tablets.; 2020. Accessed May 2, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213591s000lbl.pdf
3. Vansteenkiste JF, Van De Kerkhove C, Wauters E, Van Mol P. Capmatinib for the treatment of non-small cell lung cancer. Expert Review of Anticancer Therapy. 2019;19(8):659-671. doi:https://doi.org/10.1080/14737140.2019.1643239
4. Choi W, Park SY, Lee Y, et al. The Clinical Impact of Capmatinib in the Treatment of Advanced Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation or Gene Amplification. Cancer Research and Treatment. Published online January 29, 2021. doi:https://doi.org/10.4143/crt.2020.1331